FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Arturo Molina

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Christos Emmanouilides; Thomas E Witzig; Gregory A Wiseman; Leo I Gordon; Hua Wang; Russell J Schilder; M Wayne Saville; Ian W Flinn; Arturo Molina
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.
Myron S Czuczman; Christos Emmanouilides; Mohamed Darif; Thomas E Witzig; Leo I Gordon; Stephen Revell; Katie Vo; Arturo Molina
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
Gregory A Wiseman; Peter S Conti; Katie Vo; Russell J Schilder; Leo I Gordon; Christos Emmanouilides; Daniel H S Silverman; Thomas E Witzig; Mohamed Darif; Arturo Molina
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Arturo Molina (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Christos Emmanouilides; Thomas E Witzig; Gregory A Wiseman; Leo I Gordon; Hua Wang; Russell J Schilder; M Wayne Saville; Ian W Flinn; Arturo Molina
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.
Cancer biotherapy & radiopharmaceuticals 2007;22(5):684-91.
2007: Myron S Czuczman; Christos Emmanouilides; Mohamed Darif; Thomas E Witzig; Leo I Gordon; Stephen Revell; Katie Vo; Arturo Molina
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4285-92.
2007: Gregory A Wiseman; Peter S Conti; Katie Vo; Russell J Schilder; Leo I Gordon; Christos Emmanouilides; Daniel H S Silverman; Thomas E Witzig; Mohamed Darif; Arturo Molina
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Clinical lymphoma & myeloma 2007;7(8):514-7.
2007: Thomas E Witzig; Arturo Molina; Leo I Gordon; Christos Emmanouilides; Russell J Schilder; Ian W Flinn; Mohamed Darif; Roger M Macklis; Katie Vo; Gregory A Wiseman
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
Cancer 2007;109(9):1804-10.
2006: Christos Emmanouilides; Thomas E Witzig; Leo I Gordon; Katie Vo; Gregory A Wiseman; Ian W Flinn; Mohamed Darif; Russell J Schilder; Arturo Molina
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
Leukemia & lymphoma 2006;47(4):629-36.
2004: Stephen M Ansell; Russell J Schilder; Peter C Pieslor; Leo I Gordon; Christos Emmanouilides; Katie Vo; Myron S Czuczman; Thomas E Witzig; Charles Theuer; Arturo Molina
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
Clinical lymphoma 2004;5(3):202-4.
2004: Leo I Gordon; Thomas E Witzig; Arturo Molina; Myron S Czuczman; Christos Emmanouilides; Robin Joyce; Katie Vo; Charles Theuer; Brad Pohlman; Nancy L Bartlett; Gregory A Wiseman; Mohamed Darif; Christine White
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Clinical lymphoma 2004;5(2):98-101.
2004: Russell J Schilder; Arturo Molina; Nancy L Bartlett; Thomas E Witzig; Leo Gordon; James Murray; Stewart Spies; Hua Wang; Gregory A Wiseman; Christine White
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Cancer biotherapy & radiopharmaceuticals 2004;19(4):478-81.
2004: Leo I Gordon; Arturo Molina; Thomas E Witzig; Christos Emmanouilides; Andrew Raubtischek; Mohamed Darif; Russell J Schilder; Gregory A Wiseman; Christine White
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.
Blood 2004;103(12):4429-31.